Probiotics in Human Immunodeficiency Virus Infection: A Systematic Review and Evidence Synthesis of Benefits and Risks
People living with human immunodeficiency virus frequently use dietary supplements, including probiotics, but concern exists about ingesting live organisms. We performed a systematic review of the benefits of probiotics and a meta-analysis of sepsis risk. We undertook a protocol-driven, comprehensiv...
Gespeichert in:
Veröffentlicht in: | Open forum infectious diseases 2016-10, Vol.3 (4), p.ofw164-ofw164 |
---|---|
Hauptverfasser: | , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | ofw164 |
---|---|
container_issue | 4 |
container_start_page | ofw164 |
container_title | Open forum infectious diseases |
container_volume | 3 |
creator | Carter, George M Esmaeili, Aryan Shah, Hardikkumar Indyk, Debbie Johnson, Matthew Andreae, Michael Sacks, Henry S |
description | People living with human immunodeficiency virus frequently use dietary supplements, including probiotics, but concern exists about ingesting live organisms. We performed a systematic review of the benefits of probiotics and a meta-analysis of sepsis risk. We undertook a protocol-driven, comprehensive review to identify all relevant studies, assess their quality, and summarize the evidence. Of 2068 references, 27 were analyzed. The data suggest possible benefits for CD4 count, recurrence or management of bacterial vaginosis, and diarrhea management. We examined randomized, controlled studies explicitly assessing sepsis in any patient population, and we found zero cases of supplement-associated bacteremia or fungemia in 39 randomized controlled trials comprising 9402 subjects. The estimated number needed to harm is 7369 in Bayesian approach (95% credible interval: 1689, ∞), which should reassure clinicians. No or mild adverse effects were reported. Longer duration studies investigating different individual and mixed strains for plausible indications are needed to establish best practices. |
doi_str_mv | 10.1093/ofid/ofw164 |
format | Article |
fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_5063545</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1835444057</sourcerecordid><originalsourceid>FETCH-LOGICAL-c381t-18298b2f4633d9676d0ec8351f21cb78c1cb72d2546b21ff12e2df6cec26692d3</originalsourceid><addsrcrecordid>eNpVkc1LAzEQxYMoKtWTd8lRkGo-NtldD4KK2kJB8esadpOJRruJbnYr_e9NbRW9zAy837wZeAjtUXJEScmPg3UmlU8qszW0zTgrhkUp8vU_8xbajfGVEEIpESQvN9EWy_MsZ4Jso9ltG2oXOqcjdh6P-qbyeNw0vQ8GrNMOvJ7jJ9f2EY-9Bd254E_wGb6fxw6aKi3iO5g5-MSVN_hy5kzagCT77gWiizhYfA4-eXXxG7lz8S3uoA1bTSPsrvoAPV5dPlyMhpOb6_HF2WSoeUG7IS1YWdTMZpJzU8pcGgK64IJaRnWdF3pRmWEikzWj1lIGzFipQTMpS2b4AJ0ufd_7ugGjwXdtNVXvrWuqdq5C5dR_xbsX9RxmShDJRSaSwcHKoA0fPcRONS5qmE4rD6GPiqZvsiwjIk_o4RLVbYixBft7hhK1CEstwlLLsBK9__ezX_YnGv4FbkKTkA</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1835444057</pqid></control><display><type>article</type><title>Probiotics in Human Immunodeficiency Virus Infection: A Systematic Review and Evidence Synthesis of Benefits and Risks</title><source>DOAJ Directory of Open Access Journals</source><source>Access via Oxford University Press (Open Access Collection)</source><source>EZB-FREE-00999 freely available EZB journals</source><source>PubMed Central</source><creator>Carter, George M ; Esmaeili, Aryan ; Shah, Hardikkumar ; Indyk, Debbie ; Johnson, Matthew ; Andreae, Michael ; Sacks, Henry S</creator><creatorcontrib>Carter, George M ; Esmaeili, Aryan ; Shah, Hardikkumar ; Indyk, Debbie ; Johnson, Matthew ; Andreae, Michael ; Sacks, Henry S</creatorcontrib><description>People living with human immunodeficiency virus frequently use dietary supplements, including probiotics, but concern exists about ingesting live organisms. We performed a systematic review of the benefits of probiotics and a meta-analysis of sepsis risk. We undertook a protocol-driven, comprehensive review to identify all relevant studies, assess their quality, and summarize the evidence. Of 2068 references, 27 were analyzed. The data suggest possible benefits for CD4 count, recurrence or management of bacterial vaginosis, and diarrhea management. We examined randomized, controlled studies explicitly assessing sepsis in any patient population, and we found zero cases of supplement-associated bacteremia or fungemia in 39 randomized controlled trials comprising 9402 subjects. The estimated number needed to harm is 7369 in Bayesian approach (95% credible interval: 1689, ∞), which should reassure clinicians. No or mild adverse effects were reported. Longer duration studies investigating different individual and mixed strains for plausible indications are needed to establish best practices.</description><identifier>ISSN: 2328-8957</identifier><identifier>EISSN: 2328-8957</identifier><identifier>DOI: 10.1093/ofid/ofw164</identifier><identifier>PMID: 27747250</identifier><language>eng</language><publisher>United States: Oxford University Press</publisher><subject>Review</subject><ispartof>Open forum infectious diseases, 2016-10, Vol.3 (4), p.ofw164-ofw164</ispartof><rights>The Author 2016. Published by Oxford University Press on behalf of the Infectious Diseases Society of America. 2016</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c381t-18298b2f4633d9676d0ec8351f21cb78c1cb72d2546b21ff12e2df6cec26692d3</citedby><cites>FETCH-LOGICAL-c381t-18298b2f4633d9676d0ec8351f21cb78c1cb72d2546b21ff12e2df6cec26692d3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC5063545/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC5063545/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,864,885,27924,27925,53791,53793</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/27747250$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Carter, George M</creatorcontrib><creatorcontrib>Esmaeili, Aryan</creatorcontrib><creatorcontrib>Shah, Hardikkumar</creatorcontrib><creatorcontrib>Indyk, Debbie</creatorcontrib><creatorcontrib>Johnson, Matthew</creatorcontrib><creatorcontrib>Andreae, Michael</creatorcontrib><creatorcontrib>Sacks, Henry S</creatorcontrib><title>Probiotics in Human Immunodeficiency Virus Infection: A Systematic Review and Evidence Synthesis of Benefits and Risks</title><title>Open forum infectious diseases</title><addtitle>Open Forum Infect Dis</addtitle><description>People living with human immunodeficiency virus frequently use dietary supplements, including probiotics, but concern exists about ingesting live organisms. We performed a systematic review of the benefits of probiotics and a meta-analysis of sepsis risk. We undertook a protocol-driven, comprehensive review to identify all relevant studies, assess their quality, and summarize the evidence. Of 2068 references, 27 were analyzed. The data suggest possible benefits for CD4 count, recurrence or management of bacterial vaginosis, and diarrhea management. We examined randomized, controlled studies explicitly assessing sepsis in any patient population, and we found zero cases of supplement-associated bacteremia or fungemia in 39 randomized controlled trials comprising 9402 subjects. The estimated number needed to harm is 7369 in Bayesian approach (95% credible interval: 1689, ∞), which should reassure clinicians. No or mild adverse effects were reported. Longer duration studies investigating different individual and mixed strains for plausible indications are needed to establish best practices.</description><subject>Review</subject><issn>2328-8957</issn><issn>2328-8957</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2016</creationdate><recordtype>article</recordtype><recordid>eNpVkc1LAzEQxYMoKtWTd8lRkGo-NtldD4KK2kJB8esadpOJRruJbnYr_e9NbRW9zAy837wZeAjtUXJEScmPg3UmlU8qszW0zTgrhkUp8vU_8xbajfGVEEIpESQvN9EWy_MsZ4Jso9ltG2oXOqcjdh6P-qbyeNw0vQ8GrNMOvJ7jJ9f2EY-9Bd254E_wGb6fxw6aKi3iO5g5-MSVN_hy5kzagCT77gWiizhYfA4-eXXxG7lz8S3uoA1bTSPsrvoAPV5dPlyMhpOb6_HF2WSoeUG7IS1YWdTMZpJzU8pcGgK64IJaRnWdF3pRmWEikzWj1lIGzFipQTMpS2b4AJ0ufd_7ugGjwXdtNVXvrWuqdq5C5dR_xbsX9RxmShDJRSaSwcHKoA0fPcRONS5qmE4rD6GPiqZvsiwjIk_o4RLVbYixBft7hhK1CEstwlLLsBK9__ezX_YnGv4FbkKTkA</recordid><startdate>20161001</startdate><enddate>20161001</enddate><creator>Carter, George M</creator><creator>Esmaeili, Aryan</creator><creator>Shah, Hardikkumar</creator><creator>Indyk, Debbie</creator><creator>Johnson, Matthew</creator><creator>Andreae, Michael</creator><creator>Sacks, Henry S</creator><general>Oxford University Press</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20161001</creationdate><title>Probiotics in Human Immunodeficiency Virus Infection: A Systematic Review and Evidence Synthesis of Benefits and Risks</title><author>Carter, George M ; Esmaeili, Aryan ; Shah, Hardikkumar ; Indyk, Debbie ; Johnson, Matthew ; Andreae, Michael ; Sacks, Henry S</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c381t-18298b2f4633d9676d0ec8351f21cb78c1cb72d2546b21ff12e2df6cec26692d3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2016</creationdate><topic>Review</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Carter, George M</creatorcontrib><creatorcontrib>Esmaeili, Aryan</creatorcontrib><creatorcontrib>Shah, Hardikkumar</creatorcontrib><creatorcontrib>Indyk, Debbie</creatorcontrib><creatorcontrib>Johnson, Matthew</creatorcontrib><creatorcontrib>Andreae, Michael</creatorcontrib><creatorcontrib>Sacks, Henry S</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Open forum infectious diseases</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Carter, George M</au><au>Esmaeili, Aryan</au><au>Shah, Hardikkumar</au><au>Indyk, Debbie</au><au>Johnson, Matthew</au><au>Andreae, Michael</au><au>Sacks, Henry S</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Probiotics in Human Immunodeficiency Virus Infection: A Systematic Review and Evidence Synthesis of Benefits and Risks</atitle><jtitle>Open forum infectious diseases</jtitle><addtitle>Open Forum Infect Dis</addtitle><date>2016-10-01</date><risdate>2016</risdate><volume>3</volume><issue>4</issue><spage>ofw164</spage><epage>ofw164</epage><pages>ofw164-ofw164</pages><issn>2328-8957</issn><eissn>2328-8957</eissn><abstract>People living with human immunodeficiency virus frequently use dietary supplements, including probiotics, but concern exists about ingesting live organisms. We performed a systematic review of the benefits of probiotics and a meta-analysis of sepsis risk. We undertook a protocol-driven, comprehensive review to identify all relevant studies, assess their quality, and summarize the evidence. Of 2068 references, 27 were analyzed. The data suggest possible benefits for CD4 count, recurrence or management of bacterial vaginosis, and diarrhea management. We examined randomized, controlled studies explicitly assessing sepsis in any patient population, and we found zero cases of supplement-associated bacteremia or fungemia in 39 randomized controlled trials comprising 9402 subjects. The estimated number needed to harm is 7369 in Bayesian approach (95% credible interval: 1689, ∞), which should reassure clinicians. No or mild adverse effects were reported. Longer duration studies investigating different individual and mixed strains for plausible indications are needed to establish best practices.</abstract><cop>United States</cop><pub>Oxford University Press</pub><pmid>27747250</pmid><doi>10.1093/ofid/ofw164</doi><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 2328-8957 |
ispartof | Open forum infectious diseases, 2016-10, Vol.3 (4), p.ofw164-ofw164 |
issn | 2328-8957 2328-8957 |
language | eng |
recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_5063545 |
source | DOAJ Directory of Open Access Journals; Access via Oxford University Press (Open Access Collection); EZB-FREE-00999 freely available EZB journals; PubMed Central |
subjects | Review |
title | Probiotics in Human Immunodeficiency Virus Infection: A Systematic Review and Evidence Synthesis of Benefits and Risks |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-26T20%3A19%3A53IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Probiotics%20in%20Human%20Immunodeficiency%20Virus%20Infection:%20A%20Systematic%20Review%20and%20Evidence%20Synthesis%20of%20Benefits%20and%20Risks&rft.jtitle=Open%20forum%20infectious%20diseases&rft.au=Carter,%20George%20M&rft.date=2016-10-01&rft.volume=3&rft.issue=4&rft.spage=ofw164&rft.epage=ofw164&rft.pages=ofw164-ofw164&rft.issn=2328-8957&rft.eissn=2328-8957&rft_id=info:doi/10.1093/ofid/ofw164&rft_dat=%3Cproquest_pubme%3E1835444057%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1835444057&rft_id=info:pmid/27747250&rfr_iscdi=true |